Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2F5 + 2G12 + 4E10 (Polymun Scientific)
- Development stage
- Unknown
- Lead developer
- The Rockefeller University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination of three broadly neutralizing monoclonal antibodies (bNAbs)—2F5, 2G12, and 4E10—developed for the treatment of HIV-1 infection. These antibodies target distinct regions of the HIV-1 envelope glycoprotein: 2F5 and 4E10 target the membrane-proximal external region (MPER) of gp41, while 2G12 targets a carbohydrate-dependent epitope on gp120. The combination was evaluated by Rockefeller University in Phase I/II clinical trials to assess its safety and ability to prevent viral rebound in patients whose HIV-1 was well-suppressed by highly active antiretroviral therapy (HAART). The antibodies were manufactured by Polymun Scientific and are intended to neutralize a broad range of HIV-1 strains by blocking viral entry into host cells.
- Other names
- 2F5 + 2G12 + 4E10 cocktailRockefeller bNAb cocktail
02
Targets
gp120 glycan shield (HIV-1 gp120 glycan shield)MPER (Human immunodeficiency virus type 1 envelope glycoprotein 41)
Beyond the preview
Go deeper on 2F5 + 2G12 + 4E10 (Polymun Scientific).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2F5 + 2G12 + 4E10 (Polymun Scientific).